BioSpectrum the business of Bio & Health Sciences ASIA EDITION

Santen, Orbis to tackle increasing burden of eye diseases in Asia

October 9, 2020 | News

Santen and Orbis will accelerate the growth of quality eye care systems



Japanese firm Santen Pharmaceutical and Orbis International in the US have announced a long-term, ten-year partnership to tackle the increasing burden of eye diseases in low- and middle-income countries, especially in Asia.

Under this long-term partnership, Santen and Orbis will accelerate the growth of quality eye care systems by building the capacity of eye care professionals, developing digital technology and increasing awareness of the importance of eye health.

During the initial three years of the ten-year partnership, Santen and Orbis – through Orbis's initiatives and award-winning telemedicine platform, Cybersight, which reaches eye care professionals across 200 countries and regions – will carry out the following activities:

- Provide quality residency training and grow ophthalmologists' expertise in glaucoma, thereby building and strengthening skills that are critical to protecting vision and providing quality patient care, in Vietnam and India
- Develop digital training programs, such as artificial intelligence (AI)-augmented care and a digital surgical training platform for glaucoma, that enable greater access to patient care
- Invest in research that aims to quantify the importance of eye health, including how improved care and better vision can affect quality of life